FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors

Fri Apr 26 2024

Get AI-powered summaries and transcripts for any meeting, phone call, or podcast.

AI SummariesFull TranscriptsSpeaker Identification

Available on iOS, Android, Mac, and Windows

No transcript available.